BMC Rheumatology最新文献

{"title":"Prevalence and factors associated with fatigue in patients with psoriatic arthritis: a systematic review and meta-analysis.","authors":"Haoming Tang, Tricia Li Ting Chew, Warren Fong","doi":"10.1186/s41927-025-00498-8","DOIUrl":"https://doi.org/10.1186/s41927-025-00498-8","url":null,"abstract":"<p><strong>Objectives: </strong>Fatigue is a prominent symptom in patients with psoriatic arthritis (PsA). There was a wide variety of statistics previously reported on fatigue prevalence in patients. This systematic review examined the current literature to derive the overall prevalence of fatigue and risk factors in PsA patients.</p><p><strong>Methods: </strong>A systematic review of the literature with subsequent meta-analyses was conducted. Publications assessing fatigue severity and prevalence in patients with PsA using validated measurement scores were identified from seven online databases (Cochrane, CINAHL, EMBASE, Google Scholar, MEDLINE, PubMed, and Web of Science), from inception until January 2024. Employing a random effects model, we calculated the pooled fatigue prevalence. Quality assessment of included studies was performed utilising the Joanna Briggs Critical Appraisal Tool.</p><p><strong>Results: </strong>The final analysis included 15 studies with 6482 PsA patients. Pooled fatigue prevalence was 0.51 (95% CI: 0.41, 0.61; I2 = 97.4%). There was substantial heterogenicity across the studies, with biologics use and geographical location in terms of Western versus Eastern countries being possible sources of heterogeneity. Age, disease duration, gender, tender joint count, swollen joint and enthesitis count are among the most commonly reported risk factors for fatigue in multivariate logistic regressions.</p><p><strong>Conclusions: </strong>Approximately half of the patients with PsA experienced fatigue. Biologics use and geographical location of the study were possible sources of heterogeneity in the subgroup analysis.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"44"},"PeriodicalIF":2.1,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of foot function in terms of different pharmacological treatments in a cohort of patients with rheumatoid arthritis: a longitudinal study.","authors":"Maria Gamez-Guijarro, Andres Reinoso-Cobo, Manuel Pardo-Rios, Ana-Belen Ortega-Avila, Laura Ramos-Petersen, Gabriel Gijon-Nogueron, Eva Lopezosa-Reca","doi":"10.1186/s41927-025-00495-x","DOIUrl":"https://doi.org/10.1186/s41927-025-00495-x","url":null,"abstract":"<p><p>This study examines the influence of pharmacological treatments on foot functionality in patients with rheumatoid arthritis over a five-year period. A longitudinal analysis categorized patients into different treatment groups, assessing their foot function using the Foot Function Index (FFI) at the start and end of the study. The groups are based on their pharmacological treatment. Pharmacological treatment groups were categorized into: I methotrexate (MTX), II MTX plus biological treatments (including all variables), III biological treatment alone, and IV a miscellaneous group comprising patients with diverse treatments, including patients for whom various drugs had failed or who had not achieved remission with pharmacological treatment. The study included 206 RA patients with an average age of 58.32 years and a disease evolution of 15.28 years. The analysis of the FFI in total and across its domains of pain, disability, and activity revealed significant differences only in the pain domain (p = 0.011), with a trend toward worsening over time observed in the other domains. Notably, MTX treatment showed improvement in the pain domain (decreasing from 45.76 in 2018 to 40.43 in 2023). Findings suggest that while pharmacological treatments are essential in managing rheumatoid arthritis, their impact on foot function is limited, with MTX demonstrating the most significant benefit in terms of pain reduction.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"43"},"PeriodicalIF":2.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgA vasculitis associated with chronic myelomonocytic leukemia.","authors":"Bénédicte Rouvière, Francois Chasset, Noémie Abisror, Pierre Hirsch, Olivier Fain, Arsène Mékinian","doi":"10.1186/s41927-025-00470-6","DOIUrl":"https://doi.org/10.1186/s41927-025-00470-6","url":null,"abstract":"<p><p>IgA vasculitis is a predominantly pediatric autoimmune disease characterized by IgA deposit in small vessels. Chronic myelomonocytic leukemia (CMML) is a rare hematological malignancy classified within myelodysplastic syndromes. Here, we present a previously unrecognized case of CMML associated with IgA vasculitis. A 62-year-old woman presented with necrotic and infiltrated purpura and mild arthralgia, primarily affecting the knees and wrists, without gastrointestinal or kidney involvement. A comprehensive screening for other etiologies was unremarkable. Blood tests showed an increase of monocyte count and circulating monocyte phenotyping was consistent with CMML. Bone marrow analysis showed no blast cells or karyotypic abnormalities. Genetic testing identified an NRAS mutation. Autoantibody screening and viral serologies were negative. A skin biopsy revealed small-vessel vasculitis with IgA immune deposits. CMML can be associated with autoimmune diseases, such as polyarteritis nodosa and cutaneous leukocytoclastic vasculitis. However, this is the first report of IgA vasculitis occurring in the context of low risk CMML.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"42"},"PeriodicalIF":2.1,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do infections play a role in the development of chronic inflammatory arthritis? A 14-year follow-up study of patients with early arthritis.","authors":"Riitta Tuompo, Timo Hannu, Leena Paimela, Hannu Kautiainen, Marjatta Leirisalo-Repo, Riitta Koivuniemi","doi":"10.1186/s41927-025-00491-1","DOIUrl":"https://doi.org/10.1186/s41927-025-00491-1","url":null,"abstract":"<p><strong>Background: </strong>The role of preceding infections in the development of reactive arthritis (ReA) is well known but is less studied in association with other inflammatory arthritides. Therefore, in 1979-80 we screened for infections in patients with early musculoskeletal symptoms who were referred for rheumatological consultation and assessed the role of infections and other clinical factors in the development of chronic disease in following 14 years.</p><p><strong>Methods: </strong>A total of 104 consecutive patients with suspected inflammatory musculoskeletal symptoms with a duration < 6 months were examined and screened for preceding infections in an outpatient rheumatology clinic. Follow-up evaluation was conducted after 14 years.</p><p><strong>Results: </strong>ReA, undifferentiated arthritis, and rheumatoid arthritis were the most common diagnoses at baseline and at the 14-year follow-up. Of the 80 patients participating in the 14-year follow-up evaluation, 34 (42.5%) had had evidence of infection at baseline. Twenty-four patients (30%) had developed chronic rheumatic disease. Polyarticular disease at baseline and positive rheumatoid factors predicted the development of chronic diseases. Of the patients originally diagnosed with ReA, 7.3% proceeded to ankylosing spondylitis.</p><p><strong>Conclusion: </strong>At baseline, signs of preceding infections were detected in 41% of the patients with early musculoskeletal symptoms. Preceding infections showed no association with either specific diagnosis of arthritis, except for ReA.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"41"},"PeriodicalIF":2.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Involving young people in research investigating comorbidity associated with childhood-onset rheumatic disease: perspectives of a series of focus groups.","authors":"Sab Siddiq, Jenny Sammy Ainsworth, Clare E Pain, Eve M D Smith, Sizheng Steven Zhao, David M Hughes, Liza J McCann","doi":"10.1186/s41927-025-00492-0","DOIUrl":"https://doi.org/10.1186/s41927-025-00492-0","url":null,"abstract":"<p><strong>Background: </strong>Childhood-onset rheumatic diseases, such as juvenile idiopathic arthritis, juvenile-onset lupus and juvenile dermatomyositis, appear to be associated with an increased risk of comorbidities in adulthood compared to the general population. For the first stage of a research project evaluating this topic, we wanted to capture views from young people with juvenile-onset rheumatic disease to ensure that further work was relevant to their lived experience and priorities. This study aimed to determine (i) which comorbidities young people identify as important, (ii) how they access information about their disease, including comorbidity risk, whether (iii) they would like to hear about the risk of comorbidities whilst they are under paediatric care, and (iv) would be motivated to make lifestyle choices to decrease the risk of potential comorbidities.</p><p><strong>Methods: </strong>A topic guide based on the proposed study aims was developed, and PowerPoint slides were prepared to facilitate three focus group discussions to gain insights from young people. Focus groups were conducted via video platform, and the views of young people were assimilated using notetaking and an online interactive polling tool.</p><p><strong>Results: </strong>A total of 18 young people between 10 and 27 years of age participated in the focus groups. Mental health (including depression and anxiety) was described as important comorbidity by 17/18 (94%), followed by obesity or being overweight by 9/18 (50%), heart disease by 7/18 (39%) and stroke by 5/18 (28%) of participants. Young people reported searching United Kingdom National Health Service websites, charity resources, and Google for information on their disease and associated comorbidities. They stated that they would be willing to change their lifestyle to reduce the risk of comorbidities if information were given to them sensitively with clear practical steps for reducing risk.</p><p><strong>Conclusion: </strong>Three groups of young people identified risk of mental health issues, obesity, and cardiovascular morbidities as particularly important to them. They reported searching online platforms related to their disease and increasingly accessed online resources as they transitioned from paediatric to adult care. Participants thought it would be helpful to provide information on young people's disease and associated comorbidity in a motivational and sensitive way.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"40"},"PeriodicalIF":2.1,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effectiveness and safety of methotrexate-tacrolimus combination therapy versus methotrexate monotherapy in reducing rheumatoid arthritis flares after TNF inhibitor discontinuation: a retrospective cohort study.","authors":"Taio Naniwa, Mikiko Kajiura","doi":"10.1186/s41927-025-00489-9","DOIUrl":"10.1186/s41927-025-00489-9","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the long-term effectiveness and safety of methotrexate-tacrolimus combination therapy compared to methotrexate monotherapy in maintaining successful tumor necrosis factor (TNF) inhibitor discontinuation in rheumatoid arthritis (RA) patients.</p><p><strong>Methods: </strong>We retrospectively analyzed consecutive RA patients who discontinued TNF inhibitors after achieving disease control by October 2022 and received either methotrexate monotherapy or methotrexate-tacrolimus combination therapy for up to 10 years. Per-observation time-to-event analyses assessed treatment failure, treatment intensification, first disease flare, and irreversible functional deterioration. Mixed-effects Cox models, time-dependent Cox models without random effects, and Kaplan-Meier estimates with inverse probability weighting were applied. Safety assessment included treatment-limiting adverse events and renal function trends.</p><p><strong>Results: </strong>A total of 147 treatment lines (96 methotrexate monotherapy and 51 combination therapy) in 116 patients were analyzed. The combination therapy significantly reduced treatment failure (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.24-0.72), treatment intensification with the index drugs (HR, 0.38; 95% CI, 0.22-0.67) and with biologics or Janus kinase inhibitors (HR, 0.39; 95% CI, 0.22-0.71), and first flare (HR, 0.55; 95%CI 0.36-0.84), with consistent findings across models. The benefit was most pronounced in patients with prior flares during methotrexate monotherapy after TNF inhibitor discontinuation, with HRs as low as 0.04-0.12 across outcomes. No significant differences in treatment-limiting adverse events were observed. The annual increase in serum creatinine for tacrolimus users was 0.0032 mg/dL, suggesting minimal long-term renal impact.</p><p><strong>Conclusions: </strong>Methotrexate-tacrolimus combination therapy significantly reduces relapse risk following TNF inhibitor discontinuation without compromising safety, offering a potentially sustainable treatment alternative after achieving remission with TNF inhibitor therapy.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"39"},"PeriodicalIF":2.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of different intervention thresholds for the treatment of glucocorticoid-induced osteoporosis: a cross-sectional study.","authors":"Kanchalee Puksun, Chatlert Pongchaiyakul, Rattapol Pakchotanon, Pongthorn Narongroeknawin, Pornsawan Leosuthamas, Thunyawarin Arunthanachaikul, Sumapa Chaiamnuay","doi":"10.1186/s41927-025-00488-w","DOIUrl":"10.1186/s41927-025-00488-w","url":null,"abstract":"<p><strong>Background: </strong>Glucocorticoid-induced osteoporosis (GIO) is the most common drug-induced osteoporosis. Early detection and treatment may decrease the fragility fractures. Several GIO guidelines exist, although they vary in recommended intervention thresholds for initiating pharmacologic treatment. This study aimed to evaluate the performance of intervention thresholds in treating GIO under various guidelines.</p><p><strong>Methods: </strong>Rheumatic disease patients receiving ≥ 2.5 mg/day prednisolone or equivalent for longer than 3 months between January 2013 and 2023 were retrospectively reviewed. Patients who were previously treated with anti-osteoporotic medications or had other secondary causes of osteoporosis were excluded. Bone mineral density (BMD) and Thailand-specific FRAX with glucocorticoid adjustment (GC-FRAX) were recorded. The performances of different intervention thresholds from six GIO guidelines (ACR 2022, Belgian 2022, TOPF 2021, Korean 2018, Malaysian 2015, and Japanese 2023) were examined against the incidence of actual fragility fractures.</p><p><strong>Results: </strong>This study included 226 rheumatic patients, with a mean (SD) age of 62.9 (10.1) years. Most of the patients were female (88.9%). The average (SD) daily dose, cumulative dose, and duration of glucocorticoid use were 4.6 (10.6) mg/day, 9,223.4 (9,223.4) mg, and 58.3 (55.8) months, respectively. Diagnoses included rheumatoid arthritis (59.8%), systemic lupus erythematosus (22%), inflammatory myositis (4.7%), systemic sclerosis (4.7%), and others. The prevalence of major osteoporotic fractures and hip fractures was 14.2% and 0.9%, respectively. The ten-year probabilities of major osteoporotic and hip fractures (FRAX) with and without BMD were 12.6 ± 9.1, 5.4 ± 6, 10.7 ± 7.2, and 4.6 ± 4.8, respectively. The mean (SD) ten-year FRAX probabilities of major osteoporotic and hip fractures were 12.6% (9.1) and 5.4% (6) with the inclusion of BMD result, and 10.7% (7.2) and 4.6% (4.8) without the inclusion of the BMD result. The sensitivity, specificity and accuracy of the ACR 2022, Belgian 2022, TOPF 2021, Korean 2018, Malaysian 2015, and Japanese 2023 guidelines were 100%/ 3.1%/ 16.8%, 93.8%/ 14.4%/ 25.7%, 93.8%/ 43.8%/ 50.9%, 100%/ 17.5%/ 29.2%, 78.1%/ 62.9%/ 65% and 100%/ 24.2%/ 35%, respectively.</p><p><strong>Conclusions: </strong>Among evaluated guidelines, ACR 2022, Korean 2018, and Japan 2023 had the highest sensitivity for GIO treatment, while Malaysian 2015 showed the highest specificity and accuracy. These findings can improve clinical decision-making in GIO management for rheumatic disease patients.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"38"},"PeriodicalIF":2.1,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairment in systemic lupus erythematosus patients: prevalence and its association with quality of life.","authors":"Mir'atul Ginayah, Alvina Widhani, Riwanti Estiasari, Sukamto Koesnoe, Suzy Maria, Raden Mas Suryo Anggoro Kusumo Wibowo, Pradana Soewondo, Hamzah Shatri, Pukovisa Prawiroharjo, Nina Kemala Sari, Aulia Rizka","doi":"10.1186/s41927-025-00486-y","DOIUrl":"10.1186/s41927-025-00486-y","url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment among patients with systemic lupus erythematosus (SLE) can significantly impact quality of life (QoL). This study aimed to determine the prevalence of cognitive impairment in SLE patients using the Montreal Cognitive Assessment Indonesian version (MoCA-INA) and to assess its association with QoL.</p><p><strong>Methods: </strong>This was a cross-sectional study of SLE patients from the outpatient clinic at Cipto Mangunkusumo Hospital, Jakarta. Data collected included patient characteristics, MoCA-INA scores, the LupusQoL questionnaire, and the Hospital Anxiety and Depression Scale (HADS) scores. The independent T-test or Mann-Whitney U test was used to analyze the association between categorical independent variables and LupusQoL, while Spearman or Pearson correlation tests were used to examine the association between numerical independent variables and QoL. Other factors potentially associated with QoL - including disease duration, age, education level, comorbidities, disease activity, organ involvement, steroid dose, immunosuppressant medication, anxiety, and depression - were also assessed. A p-value < 0.05 was considered statistically significant.</p><p><strong>Results: </strong>Of the 116 subjects, 112 (96.6%) were female, with a mean age of 34.41 (± 10.15) years. Most participants had completed secondary education, were receiving corticosteroids, and had been prescribed hydroxychloroquine. The median MEX-SLEDAI score was 2.75 (range 0-6), and the most common organ involvements were mucocutaneous (90.5%) and musculoskeletal (91.4%) manifestations. The prevalence of cognitive impairment in SLE patients was 57.8%, with most patients experiencing mild cognitive impairment (98.5%). There was no significant difference in QoL between SLE patients with and without cognitive impairment (p = 0.750). Disease duration (r = 0.24, p = 0.011), anxiety (p < 0.001), and depression (p = 0.003) were significantly associated with QoL among SLE patients.</p><p><strong>Conclusions: </strong>More than half of the subjects experienced cognitive impairment. However, there was no significant difference in QoL between SLE patients with and without cognitive impairment.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"37"},"PeriodicalIF":2.1,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of digital vasculitis in anti-synthetase syndrome (Anti-OJ subtype).","authors":"Deniz Ak, Richard J Stratton","doi":"10.1186/s41927-025-00484-0","DOIUrl":"10.1186/s41927-025-00484-0","url":null,"abstract":"<p><p>Anti-synthetase syndrome is a rare autoimmune disorder characterised by the presence of autoantibodies against aminoacyl transfer RNA synthetases. We report a unique case of a 54-year-old woman with anti-OJ anti-synthetase syndrome, characterised by the atypical occurrence of digital vasculitis in conjunction with the classic manifestations of anti-synthetase syndrome. Our patient presented with digital vasculitis affecting the right third and fourth fingers, rapidly evolving interstitial lung disease of the organising pneumonia subtype, sub-clinical myositis, arthritis and mechanic's hands. Notably, she had no prior history of Raynaud's phenomenon. Serological tests revealed positive anti-OJ antibodies and weakly positive anti-MI2 antibodies. Our patient's condition was managed with intravenous methylprednisolone then after stepped down to prednisolone and mycophenolate mofetil with successful therapeutic response.Current literature primarily highlights Raynaud's phenomenon and vasculopathy-related ischemia, whether occlusive or non-occlusive in anti-synthetase syndrome. This case study identifies digital vasculitis as a distinctive complication of anti-synthetase syndrome, anti-OJ subtype. It emphasises the importance of recognising vascular complications, including vasculitis, even when classic signs like Raynaud's phenomenon are absent. Further research is crucial to fully understand the range of vascular manifestations associated with anti-synthetase syndrome.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"36"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"As long as you learn to adapt\"-a longitudinal mixed-methods study exploring the first decade with rheumatoid arthritis.","authors":"Maria Bergström, Åsa Larsson Ranada, Annette Sverker, Ingrid Thyberg, Mathilda Björk","doi":"10.1186/s41927-025-00485-z","DOIUrl":"10.1186/s41927-025-00485-z","url":null,"abstract":"<p><strong>Background: </strong>Early diagnosis and modern treatment have changed everyday life of patients with rheumatoid arthritis (RA). However, symptoms are still pronounced several years after diagnosis. The aim of this study is therefore to synthesise the perception of everyday life in men and women with contemporary treated RA over the course of the first decade after diagnosis. This will be achieved by comparing subjective experiences with quantitative measures of disability and disease activity.</p><p><strong>Methods: </strong>A longitudinal convergent mixed method was used. Thirty-one patients, clinically diagnosed with RA and ≥ 18 years of age, were recruited from the TIRA-2 project in southeast Sweden. Patients were followed over a decade regarding disease activity (DAS28), grip force (Grippit), pain intensity (VAS mm) and activity limitations (HAQ). Participation in valued life activities (VLA-swe) was assessed 10 years after diagnosis. The patients took part in individual interviews three- and ten-years post-diagnosis. Quantitative data were analysed through descriptive analyses and linear mixed models. The interviews were analysed using directed content analyses. The results from the quantitative and qualitative analyses were integrated in accordance with the chosen design.</p><p><strong>Results: </strong>Discrepancies between the quantitative and qualitative results were revealed, along with differences between sexes. Women expressed more problems related to disease activity and grip force, which did not coincide with the quantitative results. In fact, women experienced difficulties in activities despite decreased disease activity. Furthermore, their pain score changed quantitatively over time, which was not expressed in the interviews. These disconfirming results were not seen in men. Both women and men displayed confirming results regarding activity limitation. Some issues, such as with basic needs, were more visible quantitatively than through interviews.</p><p><strong>Conclusions: </strong>Men and women with contemporary treated RA still experience disability a decade after diagnosis. Additionally, patients' experiences and quantitatively measured outcomes do not always coincide. The qualitative data adds information and thereby complements the quantitative data on disability. Our results confirm the importance of person-centred rehabilitation in optimising patients' possibilities for participation in everyday life.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"35"},"PeriodicalIF":2.1,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}